A high-activity UK & EU sector, led by NHS ENGLAND, most recent listing 7 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical products Naproxen and Esomeprazole, in accordance with German social law. The contracts will be valid from February 1, 2026, to January 31, 2028, and suppliers can enter into contracts at
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical Alfacalcidol, in accordance with specific regulations, for the period from February 1, 2026, to January 31, 2028. Suppliers can enter into contracts at any time during this period, followi
This contract opportunity involves the establishment of non-exclusive discount contracts for the medications Olmesartan and Hydrochlorothiazide. These contracts will be in effect from February 1, 2026, to January 31, 2028, and can be signed at any time during this period (open-house model). Please n
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medications containing the active ingredient Timolol (ATC: S01ED01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join
This contract opportunity is for pharmaceutical companies to enter into discount agreements for the drug Epoetin beta, as part of the Open-House-Biologika process. The participating health insurance funds aim to establish uniform discount contracts without individual negotiations, ensuring no exclus
The Kaufmännische Krankenkasse (KKH) aims to establish discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a paragraph 8 of the Social Code Book V. This process will provide uniform contract conditions and acc
This contract opportunity involves establishing non-exclusive discount agreements for various active substances and combinations under Section 130a (8) of the Social Code Book V (SGB V) through an Open House procedure. Suppliers are invited to submit proposals for the supply of pharmaceuticals, whic
This announcement is not related to the awarding of a public contract as defined by the Public Procurement Directive (2014/24/EU) or competition law. To ensure broad information dissemination to interested pharmaceutical companies, this announcement is published in the Supplement to the Official Jou
The health insurance funds (whether HEK and/or hkk participate in each lot is determined by the designation of the respective lot) aim to enter into discount contracts with all suitable pharmaceutical companies according to § 130a Abs. 8 SGB V for the active ingredients, combinations of active ingre
This publication is about entering into non-exclusive discount contracts according to § 130a Abs. 8 SGB V for finished medicines containing the active ingredient Abaloparatide (ATC: H05AA04) as part of an "open-house model". Under uniform contract conditions and a standardized access procedure, all
